Iontophoretic delivery of carboplatin in a murine model of retinoblastoma

Brandy Hayden, Maria Elena Jockovich, Timothy G. Murray, Martina T. Kralinger, Monika Voigt, Eleut Hernandez, William J Feuer, Jean-Marie A Parel

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

PURPOSE. To evaluate the efficacy and dose-response of transcorneoscleral Coulomb controlled iontophoresis (CCI) of carboplatin in the treatment of retinal tumors of a murine model of retinoblastoma. METHODS. Thirty 6-week-old LHtinfBETATAG mice underwent a total of six, serial iontophoretic treatments administered two times per week using a current density of 2.57 mA/cm2 for 5 minutes. Fourteen animals received carboplatin treatments at concentrations of 1.4, 7.0, 10.0, or 14.0 mg/mL without current. Ten control mice underwent treatment with balanced saline solution. RESULTS. A dose-dependent inhibition of intraocular tumor was observed after repetitive iontophoretic treatment. At carboplatin concentrations of 7 mg/mL, 50% of the treated eyes (4/8) exhibited tumor control. No corneal toxicity was observed in eyes treated at carboplatin concentrations under 10 mg/mL. CONCLUSIONS. CCI delivery of carboplatin safely and effectively controls intraocular tumors in a dose-dependent manner in this murine model of retinoblastoma. CCI is a noninvasive, painless option for the focal delivery of carboplatin. However, further clinical and laboratory research is needed before this method of drug delivery is available for children with retinoblastoma.

Original languageEnglish
Pages (from-to)3717-3721
Number of pages5
JournalInvestigative Ophthalmology and Visual Science
Volume47
Issue number9
DOIs
StatePublished - Sep 1 2006

Fingerprint

Retinoblastoma
Carboplatin
Iontophoresis
Retinal Neoplasms
Therapeutics
Neoplasms
Sodium Chloride
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Hayden, B., Jockovich, M. E., Murray, T. G., Kralinger, M. T., Voigt, M., Hernandez, E., ... Parel, J-M. A. (2006). Iontophoretic delivery of carboplatin in a murine model of retinoblastoma. Investigative Ophthalmology and Visual Science, 47(9), 3717-3721. https://doi.org/10.1167/iovs.06-0365

Iontophoretic delivery of carboplatin in a murine model of retinoblastoma. / Hayden, Brandy; Jockovich, Maria Elena; Murray, Timothy G.; Kralinger, Martina T.; Voigt, Monika; Hernandez, Eleut; Feuer, William J; Parel, Jean-Marie A.

In: Investigative Ophthalmology and Visual Science, Vol. 47, No. 9, 01.09.2006, p. 3717-3721.

Research output: Contribution to journalArticle

Hayden, B, Jockovich, ME, Murray, TG, Kralinger, MT, Voigt, M, Hernandez, E, Feuer, WJ & Parel, J-MA 2006, 'Iontophoretic delivery of carboplatin in a murine model of retinoblastoma', Investigative Ophthalmology and Visual Science, vol. 47, no. 9, pp. 3717-3721. https://doi.org/10.1167/iovs.06-0365
Hayden B, Jockovich ME, Murray TG, Kralinger MT, Voigt M, Hernandez E et al. Iontophoretic delivery of carboplatin in a murine model of retinoblastoma. Investigative Ophthalmology and Visual Science. 2006 Sep 1;47(9):3717-3721. https://doi.org/10.1167/iovs.06-0365
Hayden, Brandy ; Jockovich, Maria Elena ; Murray, Timothy G. ; Kralinger, Martina T. ; Voigt, Monika ; Hernandez, Eleut ; Feuer, William J ; Parel, Jean-Marie A. / Iontophoretic delivery of carboplatin in a murine model of retinoblastoma. In: Investigative Ophthalmology and Visual Science. 2006 ; Vol. 47, No. 9. pp. 3717-3721.
@article{0fb2d6af12134ead9f0d0dc3fd441336,
title = "Iontophoretic delivery of carboplatin in a murine model of retinoblastoma",
abstract = "PURPOSE. To evaluate the efficacy and dose-response of transcorneoscleral Coulomb controlled iontophoresis (CCI) of carboplatin in the treatment of retinal tumors of a murine model of retinoblastoma. METHODS. Thirty 6-week-old LHtinfBETATAG mice underwent a total of six, serial iontophoretic treatments administered two times per week using a current density of 2.57 mA/cm2 for 5 minutes. Fourteen animals received carboplatin treatments at concentrations of 1.4, 7.0, 10.0, or 14.0 mg/mL without current. Ten control mice underwent treatment with balanced saline solution. RESULTS. A dose-dependent inhibition of intraocular tumor was observed after repetitive iontophoretic treatment. At carboplatin concentrations of 7 mg/mL, 50{\%} of the treated eyes (4/8) exhibited tumor control. No corneal toxicity was observed in eyes treated at carboplatin concentrations under 10 mg/mL. CONCLUSIONS. CCI delivery of carboplatin safely and effectively controls intraocular tumors in a dose-dependent manner in this murine model of retinoblastoma. CCI is a noninvasive, painless option for the focal delivery of carboplatin. However, further clinical and laboratory research is needed before this method of drug delivery is available for children with retinoblastoma.",
author = "Brandy Hayden and Jockovich, {Maria Elena} and Murray, {Timothy G.} and Kralinger, {Martina T.} and Monika Voigt and Eleut Hernandez and Feuer, {William J} and Parel, {Jean-Marie A}",
year = "2006",
month = "9",
day = "1",
doi = "10.1167/iovs.06-0365",
language = "English",
volume = "47",
pages = "3717--3721",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "9",

}

TY - JOUR

T1 - Iontophoretic delivery of carboplatin in a murine model of retinoblastoma

AU - Hayden, Brandy

AU - Jockovich, Maria Elena

AU - Murray, Timothy G.

AU - Kralinger, Martina T.

AU - Voigt, Monika

AU - Hernandez, Eleut

AU - Feuer, William J

AU - Parel, Jean-Marie A

PY - 2006/9/1

Y1 - 2006/9/1

N2 - PURPOSE. To evaluate the efficacy and dose-response of transcorneoscleral Coulomb controlled iontophoresis (CCI) of carboplatin in the treatment of retinal tumors of a murine model of retinoblastoma. METHODS. Thirty 6-week-old LHtinfBETATAG mice underwent a total of six, serial iontophoretic treatments administered two times per week using a current density of 2.57 mA/cm2 for 5 minutes. Fourteen animals received carboplatin treatments at concentrations of 1.4, 7.0, 10.0, or 14.0 mg/mL without current. Ten control mice underwent treatment with balanced saline solution. RESULTS. A dose-dependent inhibition of intraocular tumor was observed after repetitive iontophoretic treatment. At carboplatin concentrations of 7 mg/mL, 50% of the treated eyes (4/8) exhibited tumor control. No corneal toxicity was observed in eyes treated at carboplatin concentrations under 10 mg/mL. CONCLUSIONS. CCI delivery of carboplatin safely and effectively controls intraocular tumors in a dose-dependent manner in this murine model of retinoblastoma. CCI is a noninvasive, painless option for the focal delivery of carboplatin. However, further clinical and laboratory research is needed before this method of drug delivery is available for children with retinoblastoma.

AB - PURPOSE. To evaluate the efficacy and dose-response of transcorneoscleral Coulomb controlled iontophoresis (CCI) of carboplatin in the treatment of retinal tumors of a murine model of retinoblastoma. METHODS. Thirty 6-week-old LHtinfBETATAG mice underwent a total of six, serial iontophoretic treatments administered two times per week using a current density of 2.57 mA/cm2 for 5 minutes. Fourteen animals received carboplatin treatments at concentrations of 1.4, 7.0, 10.0, or 14.0 mg/mL without current. Ten control mice underwent treatment with balanced saline solution. RESULTS. A dose-dependent inhibition of intraocular tumor was observed after repetitive iontophoretic treatment. At carboplatin concentrations of 7 mg/mL, 50% of the treated eyes (4/8) exhibited tumor control. No corneal toxicity was observed in eyes treated at carboplatin concentrations under 10 mg/mL. CONCLUSIONS. CCI delivery of carboplatin safely and effectively controls intraocular tumors in a dose-dependent manner in this murine model of retinoblastoma. CCI is a noninvasive, painless option for the focal delivery of carboplatin. However, further clinical and laboratory research is needed before this method of drug delivery is available for children with retinoblastoma.

UR - http://www.scopus.com/inward/record.url?scp=33749135711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749135711&partnerID=8YFLogxK

U2 - 10.1167/iovs.06-0365

DO - 10.1167/iovs.06-0365

M3 - Article

C2 - 16936078

AN - SCOPUS:33749135711

VL - 47

SP - 3717

EP - 3721

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 9

ER -